Pacira BioSciences' Convertible Debt fell 4155.61% to $280.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $280.3 million, marking a year-over-year decrease of 4155.61%. This contributed to the annual value of $279.3 million for FY2024, which is 2992.02% down from last year.
Pacira BioSciences' Convertible Debt amounted to $280.3 million in Q2 2025, which was down 4155.61% from $279.8 million recorded in Q1 2025.
Pacira BioSciences' 5-year Convertible Debt high stood at $479.5 million for Q2 2024, and its period low was $278.9 million during Q3 2024.
Over the past 5 years, Pacira BioSciences' median Convertible Debt value was $397.7 million (recorded in 2023), while the average stood at $362.0 million.
In the last 5 years, Pacira BioSciences' Convertible Debt skyrocketed by 2696.71% in 2022 and then crashed by 4155.61% in 2025.
Pacira BioSciences' Convertible Debt (Quarter) stood at $339.3 million in 2021, then increased by 19.31% to $404.8 million in 2022, then dropped by 1.53% to $398.6 million in 2023, then fell by 29.92% to $279.3 million in 2024, then rose by 0.33% to $280.3 million in 2025.
Its last three reported values are $280.3 million in Q2 2025, $279.8 million for Q1 2025, and $279.3 million during Q4 2024.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value